Entrada Therapeutics
About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).
Stock Symbol: TRDA
Stock Exchange: NASDAQ
CONNECT
“Most targets for drug development are actually intracellular,” says Dipal Doshi, President and CEO of Entrada Therapeutics. “Think about how many drugs can be made that can help patients if we can figure out a way to effectively get inside the cell…that’s why Entrada’s important.”
36 articles with Entrada Therapeutics
-
Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel
1/5/2022
Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle therapeutics as a new class of medicines, announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately.
-
Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes
12/17/2021
Entrada Therapeutics, Inc. today announced that the Company will be added to the Russell 2000 ® and Russell 3000 ® Indexes as part of the planned fourth quarter IPO additions, effective after the U.S. market opens on December 20, 2021.
-
Entrada Therapeutics Reports Third Quarter 2021 Financial Results
12/9/2021
Entrada Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021 and highlighted recent business updates.
-
Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
11/18/2021
Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 12:10 p.m. Eastern Time.
-
Vaxxinity set its initial public offering price at $13 per share, raising $76 million. The company was launched in April via consolidation of the vaccine development efforts of COVAXX and United Neuroscience.
-
Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering
10/29/2021
Entrada Therapeutics, Inc., a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle therapeutics as a new class of medicines and aiming to become the world’s foremost intracellular therapeutics company, announced the pricing of its upsized initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share.
-
It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Entrada Therapeutics Appoints Biotech Industry Leader Mary Thistle to Its Board of Directors
5/4/2021
Entrada Therapeutics, Inc., a biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointment of Mary Thistle to its Board of Directors.
-
April springs up with showers of cash for these life sciences companies.
-
Entrada Therapeutics Announces Closing of $116 Million Series B Financing
3/31/2021
Entrada Therapeutics Inc., a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the successful completion of a $116 million Series B financing.
-
BioSpace Movers & Shakers, Jan. 8
1/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BioSpace Movers & Shakers, Dec. 11
12/11/2020
Biopharma and life science companies and organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Entrada Therapeutics Strengthens Leadership Team with Key Appointments
12/8/2020
Entrada Therapeutics, a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointments of Nerissa Kreher, M.D., as Chief Medical Officer and Kory Wentworth as Chief Financial Officer. Dr. Kreher, a physician executive with a 15-year record o
-
Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
1/8/2020
Entrada Therapeutics, Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced that it is developing ENTR-501, a novel thymidine phosphorylase enzyme replacement therapy, for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.